Welcome to CDC stacks | Multidrug-resistant tuberculosis : tools for tackling a new face of an old foe - 22089 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Multidrug-resistant tuberculosis : tools for tackling a new face of an old foe
  • Published Date:
    March 18, 2014
  • Language:
    English
Filetype[PDF-7.21 MB]


This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
Multidrug-resistant tuberculosis : tools for tackling a new face of an old foe
Details:
  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication. ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of TB Elimination. ; World Health Organization. Stop TB Department. ; ... More ▼
  • Description:
    The Public health importance of drug-resistant tuberculosis [PDF version of the PowerPoint presentation by Sarita Shah, p. 14-26] -- Rapid diagnosis of MDR TB: a laboratory systems-based approach [PDF version of the PowerPoint presentation by Tom Shinnick, p. 27-36] -- Rational use of new drugs for treatment of MDR TB: context and challenges [PDF version of the PowerPoint presentation by Christian Lienhardt, p. 37-51] -- Drug resistance in TB: what public health can do now and in the future [PDF version of the PowerPoint presentation by Tom Kenyon, p. 52-67].

    PDF file of the speakers' PowerPoint presentations at CDC Public health grand rounds: Tuesday, March 18, 2014 at 1 p.m. - 2 p.m.

    Tuberculosis is an ancient disease that remains an important global cause of morbidity and mortality. In most cases, TB can be treated and cured by taking a combination of several drugs for 6 to 12 months. When inappropriate or incomplete treatment takes place, however, TB bacteria can develop resistance to multiple drugs. Treatment of drug-resistant TB is currently longer, more toxic, more complex, and less effective than for drug-susceptible TB. In 2011, less than 10% of the total estimated multidrug-resistant TB (MDR TB) cases were detected and annually, there are approximately 500,000 cases of MDR TB, and 150,000 deaths. Although there are simple rapid tests that have improved the diagnosis of the disease, there is immense potential to increase the number of persons diagnosed with MDR TB, and diagnose them more quickly so that they can begin treatment sooner.

    Presented by: Sarita Shah, MD, MPH 
Associate Chief for Science, International Research and Programs Branch, Division of TB Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC [“The Public Health Importance of Drug-resistant Tuberculosis”]; Tom Shinnick, PhD 
Associate Director for Global Laboratory Activities, Division of TB Elimination 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC 
[“Rapid Diagnosis of MDR TB: A Laboratory Systems-based Approach”]; Christian Lienhardt, MD, DTM, MSc, PhD 
Senior Research Advisor, Stop TB Department, 
World Health Organization, Geneva, Switzerland 
[“Rational Use of New Drugs for Treatment of MDR TB: Context and Challenges”]; Tom Kenyon, MD, MPH 
Director, Center for Global Health, CDC
[“Drug Resistance in TB: What Public Health Can Do Now and in the Future”].

    Facilitated by: John Iskander, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds, Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds.

  • Document Type:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: